Main Menu

Adamas Pharmaceuticals, Inc.


Rigrodsky Law, P.A. is investigating Adamas Pharmaceuticals, Inc. (“Adamas”) regarding possible breaches of fiduciary duties and other violations of law related to Adamas’ agreement to be acquired by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, Adamas’ shareholders will receive $8.10 in cash and two non-tradeable contingent value rights collectively worth up to $1.00 per share.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 10/23/2021

* Indicates a required field.

Back to Page